...
机译:转移性结直肠癌中肝有限疾病的相关性:Fire-3 / AiO KRK0306试验的亚组结果
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
Univ Munich Inst Med Informat Biometry &
Epidemiol Munich Germany;
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
Gesundheitszentrum St Marien GmbH Onkol Haematol Amberg Germany;
Onkol Ravensburg Ravensburg Germany;
Klinikum Bayreuth GmbH Dept Med 4 Bayreuth Germany;
Hamatoonkol Tagesklin Landshut Germany;
UCT Univ Canc Ctr Inst Clin Canc Res Krankenhaus Nordwest Frankfurt Germany;
Lukaskrankenhaus Dept Med 2 Neuss Germany;
Klinikum Magdeburg gGmbH Dept Hematol Oncol &
Palliat Care Magdeburg Germany;
Klinikum Weiden Dept Internal Med 1 Weiden Germany;
Med Univ Vienna Dept Internal Med 1 Vienna Austria;
Krankenhaus Bad Cannstatt Klinikum Stuttgart Dept Med Stuttgart Germany;
Ambulantes Onkol Zentrum Ansbach Germany;
Westpfalz Klinikum Dept Internal Med 1 Kaiserslautern Germany;
Clin Darmstadt GmbH Med Clin Hematol Oncol 5 Darmstadt Germany;
Klinikum Fulda Tumorklin Fulda Germany;
Univ Med Ctr Mainz Dept Internal Med 1 Mainz Germany;
Univ Klinikum Jena Klin Innere Med 2 Abt Hamatol Onkol Jena Germany;
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
Ludwig Maximilians Univ Munchen Inst Pathol Munich Germany;
Ludwig Maximilians Univ Munchen Inst Pathol Munich Germany;
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
Ludwig Maximilians Univ Munchen Dept Internal Med Hematol &
Oncol 3 Comprehens Canc Ctr Munich;
metastatic colorectal cancer; clinical biomarker; liver-limited disease; bevacizumab; cetuximab;
机译:转移性结直肠癌中肝有限疾病的相关性:Fire-3 / AiO KRK0306试验的亚组结果
机译:转移结直肠癌患者的西汀蛋白诱导的皮肤毒性和早期肿瘤收缩的关系:随机阶段3试火-3的结果(AIO KRK0306)
机译:转移性结直肠癌几种治疗系中存活的评价:消防3试验分析(AIO KRK0306)
机译:超过750个基因的高深度测序支持肝脏有限转移性结直肠癌大多数患者的原发性肿瘤和转移的线性进展
机译:新型结肠直肠癌促进转移性疾病治疗的疗效
机译:探索原发肿瘤方面对转移性结直肠癌患者跨治疗线疗效的影响:FIRE-3分析(AIOKRK0306)
机译:后续疗法对FIRE-3 / aIO KRK0306试验结果的影响:FOLFIRI加西妥昔单抗或贝伐单抗治疗转移性结直肠癌KRas野生型肿瘤患者的一线治疗